Carna Biosciences, Inc. (4572.T)
JPY 268.0
(5.51%)
JPY 268.0
(5.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.09 Billion JPY | 12.91% |
| 2022 | -1.28 Billion JPY | -148.38% |
| 2021 | -509.4 Million JPY | 52.72% |
| 2020 | -1.08 Billion JPY | -208.47% |
| 2019 | 930.61 Million JPY | 185.81% |
| 2018 | -1.18 Billion JPY | -64.03% |
| 2017 | -714.36 Million JPY | -67.59% |
| 2016 | -258.84 Million JPY | -180.43% |
| 2015 | 507.59 Million JPY | 195.61% |
| 2014 | -775 Million JPY | -126.93% |
| 2013 | -239.29 Million JPY | 40.95% |
| 2012 | -406.33 Million JPY | -33.92% |
| 2011 | -314.39 Million JPY | 1.96% |
| 2010 | -330.15 Million JPY | -23.14% |
| 2009 | -210.22 Million JPY | 15.62% |
| 2008 | -450 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -670.86 Million JPY | -76.43% |
| 2024 Q1 | -408.65 Million JPY | -540.65% |
| 2023 Q1 | -512.47 Million JPY | 5.83% |
| 2023 Q2 | -354.23 Million JPY | 30.88% |
| 2023 Q4 | 94.84 Million JPY | 128.38% |
| 2023 FY | - JPY | 12.91% |
| 2023 Q3 | -334.23 Million JPY | 5.65% |
| 2022 Q2 | -307.67 Million JPY | -7246.88% |
| 2022 FY | - JPY | -148.38% |
| 2022 Q4 | -544.2 Million JPY | -27.18% |
| 2022 Q1 | 4.3 Million JPY | -99.34% |
| 2022 Q3 | -427.89 Million JPY | -39.08% |
| 2021 Q4 | 649.66 Million JPY | 263.98% |
| 2021 FY | - JPY | 52.72% |
| 2021 Q1 | -282.88 Million JPY | 37.14% |
| 2021 Q2 | -489.65 Million JPY | -73.09% |
| 2021 Q3 | -396.19 Million JPY | 19.09% |
| 2020 Q4 | -450.04 Million JPY | -85.27% |
| 2020 Q3 | -242.91 Million JPY | -15.46% |
| 2020 Q2 | -210.38 Million JPY | -26.44% |
| 2020 Q1 | -166.38 Million JPY | 56.94% |
| 2020 FY | - JPY | -208.47% |
| 2019 FY | - JPY | 185.81% |
| 2019 Q4 | -386.43 Million JPY | -292.34% |
| 2019 Q2 | 1.65 Billion JPY | 809.52% |
| 2019 Q1 | -233.8 Million JPY | 39.07% |
| 2019 Q3 | -98.49 Million JPY | -105.94% |
| 2018 Q2 | -248.82 Million JPY | -31.86% |
| 2018 Q3 | -327.35 Million JPY | -31.56% |
| 2018 Q1 | -188.71 Million JPY | 15.58% |
| 2018 FY | - JPY | -64.03% |
| 2018 Q4 | -383.7 Million JPY | -17.22% |
| 2017 Q3 | -187.26 Million JPY | -2.89% |
| 2017 Q2 | -182 Million JPY | -62.84% |
| 2017 Q1 | -111.77 Million JPY | -29.64% |
| 2017 FY | - JPY | -67.59% |
| 2017 Q4 | -223.55 Million JPY | -19.38% |
| 2016 Q3 | -141.75 Million JPY | -64.75% |
| 2016 Q1 | -120.97 Million JPY | -7.63% |
| 2016 FY | - JPY | -180.43% |
| 2016 Q4 | -86.21 Million JPY | 39.18% |
| 2016 Q2 | -86.04 Million JPY | 28.88% |
| 2015 FY | - JPY | 195.61% |
| 2015 Q3 | -98.41 Million JPY | -116.22% |
| 2015 Q4 | -112.4 Million JPY | -14.22% |
| 2015 Q2 | 606.87 Million JPY | 516.36% |
| 2015 Q1 | 98.46 Million JPY | 145.25% |
| 2014 Q2 | -145.1 Million JPY | -30.92% |
| 2014 FY | - JPY | -126.93% |
| 2014 Q1 | -110.84 Million JPY | -31.55% |
| 2014 Q3 | -131.31 Million JPY | 9.51% |
| 2014 Q4 | -217.6 Million JPY | -65.71% |
| 2013 Q1 | -68.35 Million JPY | 27.58% |
| 2013 Q4 | -84.26 Million JPY | -93.68% |
| 2013 Q3 | -43.5 Million JPY | 44.41% |
| 2013 Q2 | -78.25 Million JPY | -14.49% |
| 2013 FY | - JPY | 40.95% |
| 2012 Q3 | -128.74 Million JPY | -24.5% |
| 2012 Q4 | -94.39 Million JPY | 26.69% |
| 2012 FY | - JPY | -33.92% |
| 2012 Q2 | -103.4 Million JPY | 8.82% |
| 2012 Q1 | -113.41 Million JPY | -17.79% |
| 2011 Q1 | -54.79 Million JPY | 35.56% |
| 2011 Q3 | -92.91 Million JPY | -67.54% |
| 2011 Q4 | -96.28 Million JPY | -3.62% |
| 2011 FY | - JPY | 1.96% |
| 2011 Q2 | -55.45 Million JPY | -1.21% |
| 2010 FY | - JPY | -23.14% |
| 2010 Q1 | -78.6 Million JPY | 19.33% |
| 2010 Q3 | -100.43 Million JPY | -142.91% |
| 2010 Q4 | -85.03 Million JPY | 15.33% |
| 2010 Q2 | -41.34 Million JPY | 47.4% |
| 2009 FY | - JPY | 15.62% |
| 2009 Q1 | -54.06 Million JPY | 0.0% |
| 2009 Q2 | -53.42 Million JPY | 1.19% |
| 2009 Q3 | -43.11 Million JPY | 19.31% |
| 2009 Q4 | -97.43 Million JPY | -126.01% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 213.953% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -123.665% |
| GNI Group Ltd. | 14.48 Billion JPY | 107.535% |
| Linical Co., Ltd. | 1.24 Billion JPY | 187.536% |
| Trans Genic Inc. | 240.95 Million JPY | 553.112% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 19.477% |
| Soiken Holdings Inc. | -583.2 Million JPY | -87.203% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -81.031% |
| AnGes, Inc. | -8.86 Billion JPY | 87.677% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 15.069% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 85.244% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 952.242% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -26.51% |
| CanBas Co., Ltd. | 53.65 Million JPY | 2134.97% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -40.768% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -876.54% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 9.899% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 20.932% |
| PeptiDream Inc. | 7.37 Billion JPY | 114.802% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 43.422% |
| Ribomic Inc. | -1.01 Billion JPY | -7.828% |
| SanBio Company Limited | -4.52 Billion JPY | 75.872% |
| Healios K.K. | -3 Billion JPY | 63.692% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 6.348% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 21.628% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 22.127% |
| StemRIM | -2.03 Billion JPY | 46.271% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 183.569% |
| FunPep Company Limited | -952 Million JPY | -14.683% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -22.843% |
| Stella Pharma Corporation | -723.85 Million JPY | -50.829% |
| TMS Co., Ltd. | -937 Million JPY | -16.519% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -40.804% |
| Cuorips Inc. | -518 Million JPY | -110.769% |
| K Pharma,Inc. | 366.05 Million JPY | 398.254% |
| Takara Bio Inc. | 8.02 Billion JPY | 113.606% |
| ReproCELL Incorporated | 8.24 Million JPY | 13341.747% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1341.536% |
| StemCell Institute Inc. | 534.35 Million JPY | 304.318% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 545.964% |
| CellSeed Inc. | -836.51 Million JPY | -30.515% |